- KR₩802bn
- KR₩2tn
- KR₩2tn
- 45
- 76
- 57
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.24 | ||
| PEG Ratio (f) | 1.61 | ||
| EPS Growth (f) | 4.02% | ||
| Dividend Yield (f) | 0.51% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.81 | ||
| Price to Tang. Book | 1.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.42 | ||
| EV to EBITDA | 7.87 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 8.35% | ||
| Return on Equity | 5.99% | ||
| Operating Margin | 8.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 1,355,337.39 | 1,511,373.58 | 1,697,338.48 | 1,813,841.46 | 1,936,916.85 | 2,204,000 | 2,487,000 | 7.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +50.48 | -22.55 | +31.19 | +24.86 | -4.1 | -4.17 | +22.38 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.
Directors
- Yeong Hwan Yoon CHM (79)
- Nan Yeong Jung CCE (70)
- Jae Seung Yoon CCE (57)
- Jong Geun Jung MDR (56)
- Jae Chun Yoon MDR (53)
- Wu Bang Jeon MDR (52)
- Mun Gyu Baek OTH (64)
- Han Mo Kim OTH (50)
- Yil Sun Kim NID (76)
- Jung Hun Lee NID (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 10th, 1961
- Public Since
- June 26th, 1973
- No. of Shareholders
- 24,292
- No. of Employees
- 362
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Korea Exchange - KSE- Shares in Issue
- 40,890,710
- Address
- 244, Galmachi-ro, Jungwon-gu, SEONGNAM, 13211
- Web
- https://www.daewoongholdings.com/
- Phone
- +82 25508800
- Auditors
- KPMG Samjong Accounting Corp
Upcoming Events for 003090
Q2 2025 Daewoong Co Ltd Earnings Release
Similar to 003090
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Daewoong Co share price?
As of Today at 20:10 UTC, shares in Daewoong Co are trading at KR₩19,790. This share price information is delayed by 15 minutes.
How has the Daewoong Co share price performed this year?
Shares in Daewoong Co last closed at KR₩19,790 and the price had moved by +10.56% over the past 365 days. In terms of relative price strength the Daewoong Co share price has outperformed the FTSE Developed Asia Pacific Index by +11.82% over the past year.
What are the analyst and broker recommendations for Daewoong Co?
The overall consensus recommendation for Daewoong Co is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Daewoong Co dividend yield?
The Daewoong Co dividend yield is 1.01% based on the trailing twelve month period.
Does Daewoong Co pay a dividend?
Last year, Daewoong Co paid a total dividend of KR₩200, and it currently has a trailing dividend yield of 1.01%. We do not have any data on when Daewoong Co is to next pay dividends.
When does Daewoong Co next pay dividends?
We do not have data on when Daewoong Co is to next pay dividends. The historic dividend yield on Daewoong Co shares is currently 1.01%.
How do I buy Daewoong Co shares?
To buy shares in Daewoong Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Daewoong Co?
As of the previous close price of KR₩19,790, shares in Daewoong Co had a market capitalisation of KR₩802bn.
Where are Daewoong Co shares listed?
Here are the trading details for Daewoong Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 003090
What kind of share is Daewoong Co?
Based on an overall assessment of its quality, value and momentum Daewoong Co is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Daewoong Co share price forecast for 2025?
The analyst consensus target price for shares in Daewoong Co is KR₩28,243. That is 42.71% above the last closing price of KR₩19,790.
Analysts covering Daewoong Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩2,960 for the next financial year.
Find out moreWhat is the trend in the Daewoong Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Daewoong Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -16.62%.
As of the last closing price of KR₩19,790, shares in Daewoong Co were trading -9.1% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Daewoong Co PE Ratio?
The Daewoong Co PE ratio based on its reported earnings over the past 12 months is 6.24. The shares last closed at KR₩19,790.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Daewoong Co?
Daewoong Co's management team is headed by:
- Yeong Hwan Yoon - CHM
- Nan Yeong Jung - CCE
- Jae Seung Yoon - CCE
- Jong Geun Jung - MDR
- Jae Chun Yoon - MDR
- Wu Bang Jeon - MDR
- Mun Gyu Baek - OTH
- Han Mo Kim - OTH
- Yil Sun Kim - NID
- Jung Hun Lee - NID